Profilo
Charity D.
Scripture served as the Chief Development Officer at Bellicum Pharmaceuticals, Inc. from 2019 to 2024.
Prior to that, she worked as the Vice President of Business and Development Operations at ACELYRIN, Inc. She completed her undergraduate degree at Hamilton College (New York), her graduate degree at Dartmouth Medical School, and her doctorate at the University of North Carolina at Chapel Hill.
Precedenti posizioni note di Charity Scripture
| Società | Posizione | Fine |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 23/02/2024 |
| ACELYRIN, INC. | Corporate Officer/Principal | - |
Formazione di Charity Scripture
| Hamilton College (New York) | Undergraduate Degree |
| Dartmouth Medical School | Graduate Degree |
| University of North Carolina at Chapel Hill | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ACELYRIN, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
- Borsa valori
- Insiders
- Charity Scripture
